About Uncharacterized protein KIAA0513
Uncharacterized protein KIAA0513 (KIAA0513) is a protein
from Homo sapiens identified by UniProt accession
O60268, 411 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Uncharacterized protein KIAA0513 |
|---|
| UniProt accession | O60268 |
|---|
| Gene | KIAA0513 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 411 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (49)
Diseases linked to this target (Open Targets).
- adolescent idiopathic scoliosis · score 0.26
- body height · score 0.10
- BMI-adjusted waist circumference · score 0.10
- reticulocyte count · score 0.08
- triglyceride measurement · score 0.05
- kidney disease · score 0.04
- blue diaper syndrome · score 0.04
- glioblastoma multiforme · score 0.04
- hypercalcemia, infantile, 2 · score 0.03
- Abdominal Aortic Aneurysm · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60268-F1 | alphafold | PREDICTED | 69.91 | — |
Amino-acid sequence (411 residues)
METPEVPVGS LIDFGPEAPT SSPLEAPPPV LQDGDGSLGD GASESETTES ADSENDMGES PSHPSWDQDR RSSSNESFSS NQSTESTQDE ETLALRDFMR GYVEKIFSGG EDLDQEEKAK FGEYCSSENG KGREWFARYV SAQRCNSKCV SEATFYRLVQ SFAVVLFECH QMDDFGPAKN LMTMCFTYYH IGKPQLLPPE SREKPAGSID SYLKSANSWL AEKKDIAERL LKNTSARTEN VKGFFGGLET KLKGPLARRN EEDENKPQEK RPRAVTAYSP EDEKKGEKIY LYTHLKQQPI WHTLRFWNAA FFDAVHCERT KRSPTTRGDA GEEEEKREKW CHMTQEERDD SLRFNENITF GQLGTFTHNM LAFGLNKKLC NDFLKKQAVI GNLDEEQYKL LSDHIEQMAT E
Explore Uncharacterized protein KIAA0513 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets